GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

Group 1 - GeoVax Labs, Inc. is a biotechnology company focused on developing human vaccines and cancer immunotherapies [1][3] - The company will present at NobleCon20 on December 3, 2024, with a corporate update by Chairman & CEO David Dodd [1][2] - GeoVax's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine, currently in multiple Phase 2 clinical trials [3] Group 2 - GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients, a booster for patients with chronic lymphocytic leukemia, and a durable booster for healthy patients [3] - The company is also developing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, with a Phase 2 trial planned for 2025 [3] - GeoVax holds a strong intellectual property portfolio and worldwide rights for its technologies and products [3]